FDA Expands Approval for Enhertu®
The FDA expanded approval for fam-trastuzumab deruxtecan-nxki (Enhertu®) in combination with pertuzumab (Perjeta®) as first-line treatment of people with HER2+ MBC. Click to learn more about this new approval.
Updated Version of The Insider’s Guide to Metastatic Breast Cancer Now Available
The Insider’s Guide to Metastatic Breast Cancer is a free book with practical advice about living with MBC and the latest research into the disease. Access the 2024 most recent update here which also includes information on MBC clinical trials.
FDA Approves Inluriyo™
Read about the recent approval of Inluriyo™ for some people with ER-positive, HER2-negative MBC with an ESR1 gene mutation.
FDA Approves Enhertu® for Hormone Receptor-Positive, HER2-Low or HER2-Ultralow MBC
Read about the expanded approval of Enhertu® for some people with HR+, HER2-low or HER2-ultralow MBC based on clinical trial results.
FDA Approves Datroway®
Read about the new approval of a new drug for some people with HR+, HER2- MBC based on clinical trial results.
FDA Approves Itovebi
Read about the new approval of a new drug for some people with MBC based on clinical trial results.
FDA Approves Itovebi
Read about the new approval of a new drug for some people with MBC based on clinical trial results.
FDA Approves Truqap
Read about the new approval of a targeted therapy for some people with HR+, HER2- MBC based on clinical trial results.
